The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Tolerability and efficacy of chemotherapy in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial.
B. Seruga
No relevant relationships to disclose
A. M. Horgan
No relevant relationships to disclose
G. R. Pond
No relevant relationships to disclose
S. M. H. Alibhai
No relevant relationships to disclose
E. Amir
No relevant relationships to disclose
R. De Wit
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Research Funding - Sanofi
M. A. Eisenberger
No relevant relationships to disclose
I. Tannock
No relevant relationships to disclose